IPAROMLIMAB AND TUVONRALIMAB INJECTION
Clinical trials for IPAROMLIMAB AND TUVONRALIMAB INJECTION explained in plain language.
Never miss a new study
Get alerted when new IPAROMLIMAB AND TUVONRALIMAB INJECTION trials appear
Sign up with your email to follow new studies for IPAROMLIMAB AND TUVONRALIMAB INJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple combo aims to break through treatment barriers for advanced colorectal cancer
Disease control Recruiting nowThis early-phase trial tests a combination of immune cells (DC-CIK), a bispecific antibody, and a targeted drug as a third-line treatment for advanced colorectal cancer. It enrolls 14 adults who have failed standard therapies. The goal is to see if this triple therapy can shrink …
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated May 26, 2026 11:56 UTC
-
New hope for tough liver cancer: combo therapy targets tumors with vein clots
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706), a targeted therapy (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has spread into the main portal vei…
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 22, 2026 14:03 UTC